{"filings":[{"id":2088570,"accession_number":"0001171843-26-005294","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2026-08-06T12:00:37+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q2 net loss narrows to $1.5M; cash runway through Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.5M ($0.14 per share) vs $15.9M ($1.53) in Q2 2025; improvement driven by $3.0M warrant fair value gain.","Cash, equivalents and investments $30.4M at June 30, 2026, down from $77.8M at Dec 31, 2025; expects funding through Q4 2026.","Received $25M upfront from Amoytop for Greater China license of pevifoscorvir sodium; $3M milestone from ALG-170675 IND approval expected Q3 2026.","Phase 2 B-SUPREME study of pevifoscorvir sodium fully enrolled (245 participants); topline data expected late Q3 2027.","R&D expenses rose to $24.1M from $14.0M due to Phase 2 trial costs; G&A flat at $5.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1303756,"accession_number":"0001193125-26-285426","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2026-06-26T20:02:26+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Aligos stockholders reelect two Class III directors, approve ESPP amendment adding 500K shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Bridget Martell and Carole Nuechterlein elected as Class III directors with 2,092,164 and 2,086,481 votes for, respectively.","Stockholders approved ESPP amendment increasing share reserve by 500,000 shares to 694,714 total, and eliminating evergreen provision.","Ratification of Ernst & Young as auditor for fiscal 2026 approved with 3,786,255 votes for.","Non-binding advisory say-on-pay approved with 2,074,434 votes for; company will hold future advisory votes annually.","Stockholders voted 2,077,884 for annual frequency of say-on-pay; board adopts annual vote until next advisory vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95535,"accession_number":"0001171843-26-003156","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q1 net loss $23M; fast track for HBV drug; Amoytop license $25M upfront","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Fast Track Designation from FDA for pevifoscorvir sodium for chronic HBV infection.","Phase 2 B-SUPREME interim analysis: DSMB recommended increasing HBeAg- sample size to 100; futility criteria not met.","Exclusive license with Amoytop for Greater China: $25M upfront, up to $420M milestones plus tiered royalties.","Cash, equivalents, investments $54.9M at March 31, 2026 (Dec 31, 2025: $77.8M); expected to fund into Q4 2026 inclusive of $25M upfront.","Net loss Q1 2026: $23.0M ($2.21/share) vs net income $43.1M ($5.12/share) in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":2830000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95534,"accession_number":"0001193125-26-166987","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Aligos licenses pevifoscorvir sodium to Amoytop for China/Taiwan/HK/Macau; upfront $25M, milestones up to $420M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive license to develop and commercialize pevifoscorvir sodium for HBV and HBV/HDV in mainland China, Taiwan, Hong Kong, and Macau.","Upfront cash payment of $25 million from Amoytop; eligible for up to $420 million in development, regulatory, and commercial milestones.","Tiered high single-digit royalties on net sales in the Territory.","Amoytop responsible for all development, regulatory, manufacturing, and commercialization costs in the Territory.","Effectiveness conditional on Amoytop shareholder approval within 45 days of signing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95533,"accession_number":"0001193125-26-154927","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aligos: Phase 2 HBV interim – DSMB ups HBeAg- sample size to 100; FDA Fast Track granted","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB recommended increasing HBeAg- cohort from 74 to 100 participants to optimize power; futility criteria not met.","Study drugs well-tolerated; no viral breakthrough; safety data reviewed across all 174 enrolled participants.","FDA granted Fast Track Designation for pevifoscorvir sodium based on 96-week Phase 1 data.","Topline data from B-SUPREME study remains on track for 2027; enrollment in HBeAg- cohort expected by H2 2026.","Aligos remains blinded to participant-level data; 103 enrolled in HBeAg+ cohort (Part 1a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108677,"accession_number":"0001171843-26-001340","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos reports Q4/FY2025 net loss of $19.9M and $24.2M; cash $77.8M; Phase 2 HBV study progressing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2025 $19.9M ($1.91/sh) vs $82.2M ($13.08/sh) in Q4 2024; FY2025 net loss $24.2M ($2.45/sh) vs $131.2M ($20.94/sh) in FY2024.","Cash, cash equivalents and investments $77.8M as of Dec 31, 2025, up from $56.9M; funding expected into Q3 2026.","Phase 2 B-SUPREME study of pevifoscorvir sodium completed 60 HBeAg- enrollment; topline data expected 2027.","ALG-170675 ASO advanced to IND-enabling studies with partner Amoytop; Amoytop funds China development.","James Hassard appointed EVP, Chief Commercial Officer; ALG-055009 preclinical data showed synergistic weight loss with incretins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108676,"accession_number":"0001193125-26-037558","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aligos Therapeutics appoints Nikhil Aneja as Principal Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nikhil Aneja appointed Principal Accounting Officer effective January 29, 2026.","He succeeds Lesley Ann Calhoun, who remains EVP, COO & CFO.","Aneja has served as VP Finance since Feb 2024; prior roles at CareDx, Blade Therapeutics, Global Blood Therapeutics.","Aneja, age 49, is a CPA with a Bachelor of Commerce from University of Delhi."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125123,"accession_number":"0001171843-25-007075","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q3 net loss $31.5M; Phase 2 HBV study enrolling; cash $99.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $31.5M in Q3 2025 vs $19.3M in Q3 2024; diluted EPS loss of $3.04.","Cash, cash equivalents and investments $99.1M as of Sep 30, 2025; runway into Q3 2026.","Phase 2 B-SUPREME trial of pevifoscorvir sodium (CAM-E) for chronic HBV enrolled first patient Aug 2025; interim data 2026.","Preclinical combo data with ALG-055009 (THR-β) and incretin RAs showed synergistic weight loss; out-licensing discussions ongoing.","R&D expenses rose to $23.9M (from $16.8M) driven by Phase 2 costs; G&A $5.2M (from $4.6M) due to legal."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":2017000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141834,"accession_number":"0001171843-25-005116","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q2 net loss $15.9M, cash $122.9M; Phase 2 HBV study dosing imminent","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.9M ($1.53/sh) vs net income of $5.1M ($0.81/sh) in Q2 2024, driven by change in warrant fair value.","Cash, cash equivalents and investments $122.9M as of June 30, 2025, expected to fund operations into H2 2026.","Phase 2 B-SUPREME study of ALG-000184 (HBV) starting; interim data expected 2026, topline 2027.","ALG-055009 (MASH) Phase 2a data presented; company evaluating partnership options for continued development.","R&D expenses fell to $14.0M from $21.1M YoY due to MASH trial completion, offset by HBV program spend."],"consensus_eps_estimate":null,"consensus_eps_actual":2.9,"consensus_revenue_estimate":null,"consensus_revenue_actual":1276000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159762,"accession_number":"0001193125-25-148905","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Aligos stockholders approve charter amendments increasing authorized shares 5x and 2020 Plan share reserve by 1M","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved increase in authorized voting common stock from 20M to 100M shares.","Stockholders approved increase in authorized non-voting common stock from 800k to 15.8M shares.","Stockholders approved amendment to 2020 Plan adding 1M shares to the share reserve.","All three Class II director nominees (Hirth, Preston, Chavez) were elected with ~2.16M votes for.","Ratification of Ernst & Young as independent auditor for FY2025 approved with 3.43M votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159761,"accession_number":"0001171843-25-002781","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos raises >$100M, posts Q1 net income $43.1M; HBV drug Phase 2 to start mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash grew to $137.9M after raising over $100M; expected to fund operations into H2 2026.","Q1 2025 net income $43.1M (basic EPS $5.12); diluted net loss per share ($2.11) due to warrant fair value change.","Phase 2 B-SUPREME study of ALG-000184 in chronic HBV expected to begin mid-2025; interim data 2026, topline 2027.","ALG-055009 (THR-β agonist) Phase 2a HERALD showed placebo-adjusted median liver fat reduction up to 46.2%; up to 70% subjects achieved ≥30% reduction.","ALG-097558 pan-coronavirus inhibitor has 3 clinical trials ongoing; NIAID study Q2 2025. Company seeking external funding for further development."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":311000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178138,"accession_number":"0001171843-25-001352","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q4 net loss $82.2M; cash $56.9M; ALG-000184 Phase 2 mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss $82.2M ($13.08/share) vs $27.9M ($5.50) in Q4 2023; full-year net loss $131.2M vs $87.7M.","Cash & investments $56.9M at Dec 31, 2024; $105M private placement closed Feb 2025 extends runway into H2 2026.","Lead CAM-E candidate ALG-000184 Phase 2 expected to start mid-2025; 96-week data to be presented in 2025.","THR-β agonist ALG-055009 for MASH showed up to 46.2% placebo-adjusted median relative liver fat reduction at Week 12.","Lesley Ann Calhoun promoted to EVP, COO and CFO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178137,"accession_number":"0001193125-25-024838","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2025-02-12T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Aligos Therapeutics secures $105M private placement to fund Phase 2 hepatitis B study","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$105M from sale of 2.1M shares, pre-funded warrants (1.9M shares), and warrants (2.0M shares); closing expected Feb 13, 2025.","Combined price $26.0825 per share/warrant; warrants exercisable at $26.02, expire Feb 13, 2032; pre-funded warrants at $0.0001.","Net proceeds to fund ALG-000184 Phase 2 study in chronic hepatitis B; cash runway extended into H2 2026.","Placement led by life sciences investor; Jefferies and Piper Sandler as agents; lead investor gets board nomination rights.","Company to file resale registration statement within 45 days; securities sold in private placement exempt from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178136,"accession_number":"0001193125-25-019256","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2025-02-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aligos Therapeutics appoints Lesley Ann Calhoun as COO while retaining CFO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lesley Ann Calhoun appointed COO effective January 30, 2025, adding to existing CFO role.","She has served as EVP and CFO since June 2020; prior roles at Global Blood Therapeutics and Hyperion Therapeutics.","Calhoun brings over 30 years of finance and operations experience, including audit at Deloitte & Touche."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194800,"accession_number":"0001171843-24-006057","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q3 net loss $19.3M; MASH drug shows up to 46.2% liver fat reduction","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.3M ($3.07 per share) vs $18.0M ($10.37 per share) in Q3 2023.","Cash & investments $74.9M, down from $135.7M at Dec 31, 2023; runway through end of 2025.","MASH candidate ALG-055009 achieved placebo-adjusted median relative liver fat reduction up to 46.2% at Week 12; favorable tolerability.","CHB candidate ALG-000184 progressing to Phase 2 next year; FDA and China NMPA agree on primary endpoint.","COVID protease inhibitor ALG-097558 to begin externally funded clinical studies in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":3005000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211094,"accession_number":"0001193125-24-214188","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aligos Therapeutics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Sept 3, 2024 confirming compliance with Minimum Bid Price Requirement.","Previous deficiency letter was dated Sept 5, 2023; stock had closed below $1.00 for 30 consecutive days.","Compliance achieved under Nasdaq Listing Rules 5450(a)(1) and 5550(a)(2); matter is closed.","No additional financial or operational details provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211093,"accession_number":"0001193125-24-202813","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-08-19T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Aligos Therapeutics effects 1-for-25 reverse stock split to meet Nasdaq listing requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-25 effective 12:01 a.m. ET on August 19, 2024; trading symbol ALGS unchanged.","Split intended to bring company into compliance with Nasdaq minimum bid price for continued listing.","Every 25 pre-split shares reclassified into one new share; par value unchanged at $0.0001.","No fractional shares issued; holders entitled to cash payment based on August 16, 2024 closing price.","Board approved split on July 24, 2024; final ratio set by Reverse Split Committee on August 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211092,"accession_number":"0001193125-24-196966","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aligos appoints Heather Preston and Margarita Chavez to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to seven directors; Preston and Chavez appointed as Class II directors through 2025 annual meeting.","Dr. Preston will chair the Nominating Committee; Ms. Chavez joins the Audit Committee.","Each receives $40k annual retainer (prorated) and an initial option for 120,000 shares.","Chavez gets additional $7,500/yr for Audit; Preston gets $8,000/yr for Nominating chair (both prorated).","Both entered standard indemnification agreements; no material relationships requiring disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211091,"accession_number":"0001171843-24-004482","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q2 net income $5.1M on warrant revaluation; HERALD topline due early Q4","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $94.5M at June 30, down from $135.7M year-end; runway through end of 2025.","Net income of $5.1M ($0.03/sh) vs net loss of $18.8M (-$0.43) YoY; non-cash warrant income $30.5M.","R&D spend $21.1M (+26% YoY) on clinical trial costs; G&A $6.4M (-30% YoY).","ALG-055009 (MASH) HERALD enrollment complete; topline data expected early Q4 2024.","ALG-000184 (CHB) showed sustained HBV DNA suppression in 90-100% of subjects; FDA supports registration endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":1755000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229609,"accession_number":"0001193125-24-172218","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["5.02","5.07","5.03","9.01"],"status":"ready","headline":"Aligos stockholders approve increase in authorized shares from 300M to 500M and amendment to 2020 incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved increase in authorized shares from 300M to 500M, effective June 27, 2024.","Approved amendment to 2020 incentive plan to treat pre-funded warrants with exercise price ≤ $0.01 as common stock for annual share increases.","Board authorized to effect reverse stock split if deemed in best interests; no immediate action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229608,"accession_number":"0001193125-24-151729","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aligos receives Nasdaq notice for Audit Committee noncompliance; cure period to Nov 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Jack Nielsen resigned from Board and Audit Committee on May 21, 2024, causing noncompliance with Rule 5605.","Nasdaq granted cure period until Nov 18, 2024, as next annual meeting is June 27, 2024.","Company plans to appoint a third independent director to the Audit Committee before the cure deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229607,"accession_number":"0001193125-24-144929","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["3.01","5.02"],"status":"ready","headline":"Jack Nielsen resigns from board; Aligos out of compliance with Nasdaq Audit Committee rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Director Jack Nielsen resigned effective May 21, 2024 for personal reasons; no disagreement with company.","Audit Committee now has two members; Nasdaq requires three under Rule 5605(c)(2)(A).","Company notified Nasdaq of non-compliance on May 22, 2024 and plans to cure within 180-day period.","Aligos intends to appoint a qualified third director to Audit Committee within the cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229606,"accession_number":"0001193125-24-139476","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aligos Therapeutics Chief Medical Officer Matthew McClure resigns effective May 9, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Matthew McClure resigned as Chief Medical Officer on May 9, 2024.","No replacement or interim CMO was announced in the filing.","The departure follows Aligos's focus on antiviral therapeutics; impact on pipeline unclear."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229605,"accession_number":"0001171843-24-002612","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q1 net loss $34.9M; Phase 2a HERALD study commenced, topline expected Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $34.9M ($0.22 per share) vs $23.0M ($0.53) in Q1 2023; increase due to non-cash warrant liability charge.","Cash and investments $112.7M, down from $135.7M at Dec 2023; runway through end of 2025.","Phase 2a HERALD study (ALG-055009 for MASH) started dosing April 2024; topline data expected Q4 2024.","Received additional $1.3M NIH grant for pan-coronavirus protease inhibitor ALG-097558; Phase 2 enabling activities underway."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":694000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248135,"accession_number":"0001171843-24-001294","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q4 net loss $27.9M ($0.22/sh); cash $135.7M; HERALD data expected Q4 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $135.7M as of Dec 31, 2023; raised $92.1M in Oct 2023 PIPE; runway through end of 2025.","Q4 2023 net loss $27.9M ($0.22/sh) vs $21.9M ($0.51/sh) in Q4 2022; full year net loss $87.7M ($1.36/sh).","ALG-055009 Phase 2a HERALD (MASH) first subject dosed expected Q2 2024; topline data anticipated Q4 2024.","ALG-000184 (CHB) Phase 1b continues; interim data presentations planned at APASL, EASL, AASLD 2024.","ALG-097558 pan-coronavirus protease inhibitor Phase 1 nearing completion; topline data at ECCMID April 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248134,"accession_number":"0001193125-24-050987","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aligos Therapeutics completes stock option exchange; 93% of eligible underwater options surrendered.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Option exchange program closed; 3,880,332 shares surrendered (~93% of eligible) for 1,906,153 replacement options.","CEO Lawrence M. Blatt surrendered 854,250 options, received 421,100 replacement options; other NEOs and directors also participated.","Exchange ratios were 1.4-for-1 or 3.4-for-1 based on exercise price; all surrendered options were underwater.","Replacement options have a new one-year cliff vest from grant date (Feb 28, 2024), then follow original schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248133,"accession_number":"0001193125-24-014769","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2024-01-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aligos launches voluntary option exchange program for underwater stock options","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Eligible options have exercise price >= $2.10, granted under 2020 plan, held by US/Switzerland employees or directors.","Replacement options cover fewer shares per specified exchange ratios and are subject to new vesting schedule.","Program not yet commenced; final terms to be announced via Schedule TO tender offer.","Education session for eligible participants scheduled for January 30, 2024 at 2:00 pm PT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265598,"accession_number":"0001193125-23-282236","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2023-11-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"President Leonid Beigelman resigns; severance includes 6 months salary, 12 months COBRA","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Leonid Beigelman, President, resigned effective Nov 20, 2023; entered into separation agreement.","Separation agreement includes general release of claims and standard restrictive covenants.","Severance includes 6 months of current base salary and COBRA continuation at company expense for 12 months.","Agreement to be filed as exhibit to 2023 Form 10-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265597,"accession_number":"0001193125-23-277877","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2023-11-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aligos Therapeutics President and Board member Leonid Beigelman resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Leonid Beigelman resigned from the Board effective Nov 9, 2023.","Beigelman also resigned as President effective Dec 1, 2023.","Resignation is not related to any disagreement with the Company.","No replacement for President has been announced.","Beigelman's departure removes a key scientific leader from management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265596,"accession_number":"0001171843-23-006671","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q3 net loss $18.0M ($0.41/shr); raises $92M in October PIPE","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.0M ($0.41 per share) vs $18.6M ($0.44) in Q3 2022.","Cash, equivalents & investments $70.4M at Sep 30, down from $125.8M at Dec 31, 2022.","Closed $92M private placement in October 2023; projects cash runway through end of 2025.","FDA cleared IND for NASH THR-β agonist ALG-055009; Phase 2a startup underway.","Awarded $8.5M NIAID contract to advance coronavirus protease inhibitor ALG-097558."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":5519000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265595,"accession_number":"0001193125-23-263158","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Aligos raises $92M in private placement of shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $92.15M from sale of 31.4M shares, 81.1M pre-funded warrants, and 56.2M common warrants.","Combined price per share + common warrant is $0.8193; per pre-funded warrant + common warrant is $0.8192.","Common warrants have exercise price $0.7568 and expire Oct 25, 2030; pre-funded warrants have $0.0001 exercise price.","Closing occurred Oct 25, 2023; executives and directors entered lock-up agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265594,"accession_number":"0001193125-23-258115","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2023-10-18T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aligos settles Janssen lawsuit; dismisses counterclaims, releases all parties","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement agreement entered Oct 16, 2023 with Janssen Biotech resolving breach of contract and tortious interference claims.","Janssen dismisses action and releases Aligos, CEO Lawrence Blatt, and President Leonid Beigelman from all claims.","Aligos dismisses counterclaims for unfair competition and promissory fraud and releases Janssen.","No admission of liability or financial terms of settlement disclosed in the filing.","Litigation involved intellectual property ownership and claims against top executives."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282804,"accession_number":"0001193125-23-230611","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2023-09-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Aligos receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Notice on Sep 5, 2023: stock failed to maintain $1.00 minimum bid for 30 consecutive business days through Sep 1.","Company has 180 calendar days, until Mar 4, 2024, to regain compliance by closing at $1.00 for 10 consecutive days.","If not cured, Aligos may be eligible for an additional 180-day period by transferring to Nasdaq Capital Market.","Company intends to monitor bid price and consider options, but compliance is not assured.","Potential delisting could occur if Staff determines cure is unlikely or other standards unmet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282803,"accession_number":"0001171843-23-004975","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos reports Q2 net loss $18.8M; cash $90.8M; NASH program on track for Q4 Phase 2a filing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.8M ($0.43/shr) vs $19.9M ($0.47) in Q2 2022.","Cash $90.8M at June 30, 2023, down from $125.8M; sufficient through end 2024.","NASH candidate ALG-055009 Phase 1 complete; Phase 2a protocol filing expected Q4 2023; topline data Q4 2024.","COVID-19 protease inhibitor ALG-097558: first-in-human dosing ongoing; topline data H1 2024.","Agreement in principle with Janssen to resolve litigation; case stayed July 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":4434000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282802,"accession_number":"0001193125-23-200617","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aligos and Janssen reach agreement in principle to settle legal disputes","summary_kind":"llm","event_type":"litigation","confidence":"medium","bullets":["Stipulation to stay case filed July 31, 2023.","Agreement in principle reached to resolve ongoing disputes with Janssen Biopharma.","Parties expect to finalize settlement promptly; no financial terms disclosed.","Litigation previously involved undisclosed claims; resolution removes legal overhang."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282801,"accession_number":"0001193125-23-193424","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aligos shareholders elect three Class III directors and ratify Ernst & Young as auditor at 2023 Annual Meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Jack B. Nielsen (20,201,692 For), Bridget Martell (24,022,757 For), and Carole Nuechterlein (21,653,372 For) elected as Class III directors with 9,713,860 broker non-votes.","Ernst & Young ratified as independent auditor for FY2023: 34,670,204 For, 11,096 Against, 918 Abstain.","As of record date May 23, 2023, 40,410,244 shares were outstanding and entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302132,"accession_number":"0001171843-23-002889","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Therapeutics Q1 net loss narrows to $23.0M; NASH and COVID programs on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments $103.5M as of March 31, 2023, vs $125.8M at Dec 31, 2022.","Net loss $23.0M ($0.53 per share) compared to $35.6M ($0.84) in Q1 2022.","R&D expenses decreased to $18.1M from $31.7M YoY due to wind-down of STOPS and ASO programs.","NASH gel cap formulation selected; Phase 2 IND filing remains on track for Q4 2023.","COVID-19 protease inhibitor CTA submitted in UK; first-in-human dosing expected mid-2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":140000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321806,"accession_number":"0001171843-23-001548","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos reports FY2022 net loss of $96M; provides pipeline updates for NASH, COVID-19, HBV","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss FY2022 $96.0M ($2.25/share) vs $128.3M ($3.22) in FY2021; cash $125.8M as of Dec 31, 2022.","NASH candidate ALG-055009 Phase 1 data positive; on track for Phase 2 filing by end 2023.","COVID-19 candidate ALG-097558 to enter clinic in Q2 2023; top line data expected Q4 2023.","HBV CAM-E ALG-000184 shows HBsAg reductions; 48-week data expected in 2023.","HBV siRNA ALG-125755 SAD in healthy volunteers completed; now evaluating in CHB subjects."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339908,"accession_number":"0001171843-22-007002","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q3 net loss $18.6M, cash $142.3M; HBV and NASH programs advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.6M ($0.44 per share) vs $33.1M ($0.78) a year ago; R&D spending fell to $17.8M.","Cash, equivalents, and investments $142.3M as of Sep 30, 2022, down from $205.8M at Dec 31, 2021.","HBV CAM ALG-000184 initiated up-to-48-week dosing; siRNA ALG-125755 SAD in healthy volunteers ongoing.","NASH THR-beta agonist ALG-055009 MAD data to be presented at AASLD; plans to advance to Phase 2.","Pan-coronavirus protease inhibitor ALG-097558 entering Phase 1 enabling studies; clinical eval expected Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.74,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":357208,"accession_number":"0001171843-22-005357","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos reports Q2 net loss $19.9M ($0.47), cash $159.3M, advances HBV/siRNA programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.9M ($0.47/share) vs $29.8M ($0.79) in Q2 2021.","Cash & investments $159.3M at June 30, 2022 (down from $205.8M at Dec 31, 2021); funds ops into H1 2024.","R&D expenses decreased to $16.5M from $24.6M YoY, reflecting STOPS/ASO wind-down.","Completed enrollment in multiple CAM-2 and NASH Phase 1 cohorts; on track to file CTA for siRNA ALG-125755 in Q3 2022.","COVID-19 3CL PI ALG-097558 shows only 3-fold EC50 shift against resistant mutant vs >50-fold for nirmatrelvir."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375802,"accession_number":"0001193125-22-182802","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2022-06-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aligos Therapeutics reports annual meeting vote results; directors elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Class II directors: Thomas Woiwode (21.3M for, 4.2M withheld), Leonid Beigelman (21.5M for, 4.0M withheld), K. Peter Hirth (21.9M for, 3.6M withheld).","Ratification of Ernst & Young as auditor for FY2022 passed with 29.5M for, 90k against, 125 abstentions.","Broker non-votes of ~4.0M shares on director election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":375801,"accession_number":"0001171843-22-003216","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2022-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q1 net loss $35.6M (-$0.84/sh); HBV STOPS/ASO programs terminated; cash $183.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $35.6M ($0.84 per share) vs $27.7M ($0.74) in Q1 2021; R&D expense rose to $31.7M.","Cash, equivalents and marketable securities $183.2M at March 31, 2022; runway into first half 2024.","Terminated STOPS and ASO HBV programs in Q1 due to insufficient antiviral activity and poor tolerability.","ALG-000184 (HBV CAM) 28-day top-line data expected Q2 2022; 12-week cohort initiating Q3.","COVID PI candidate ALG-097558 7-20x more potent than nirmatrelvir vs variants; Phase 1 CTA planned H2 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394134,"accession_number":"0001193125-22-088448","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2022-03-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aligos Therapeutics sued by Janssen over breach of contract, IP ownership","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Janssen Biopharma filed complaint in Superior Court of California, San Mateo County on March 26, 2022.","Alleges breach of contract by CEO Lawrence Blatt and President Leonid Beigelman, tortious interference by Aligos.","Janssen seeks declaratory judgment on IP ownership, injunctive relief, and monetary damages.","Company believes allegations are without merit and intends to defend vigorously."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394133,"accession_number":"0001193125-22-081126","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2022-03-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aligos discontinues hepatitis B drug ALG-020572 after patient hospitalized with ALT flare","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued ALG-020572 (ASO for chronic hepatitis B) after one subject hospitalized and three others experienced ALT flares following 210 mg multiple dosing.","Dosing in first CHB cohort of Study 401 stopped after serious adverse event (ALT increase, brief hospitalization).","All four affected subjects improving; hospitalized subject discharged. No further details on safety provided.","Cost savings from discontinuation to fund clinical and preclinical programs in CHB, NASH, and COVID-19."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394132,"accession_number":"0001171843-22-001773","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2022-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q4 2021 net loss $37.7M; cash $205.8M; pipeline advances with 3 candidates in clinic","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2021 $37.7M ($0.89/share) vs $34.4M in Q4 2020; full year loss $128.3M ($3.22/share).","Cash and investments $205.8M at Dec 31, 2021; sufficient to fund operations into first half 2024.","CAM (ALG-000184) shows best-in-class HBV DNA/RNA reductions; 12-week studies planned for H2 2022.","ASO (ALG-020572) Phase 1b in CHB initiated, first cohort enrolled; data expected at a conference in H2 2022.","Expanded Merck NASH collaboration for second oligonucleotide target; COVID-19 3CL PI candidates more potent than nirmatrelvir."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":394131,"accession_number":"0001193125-22-003165","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2022-01-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Aligos halts ALG-010133 development after Phase 1 data show no meaningful HBsAg reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Halted development of STOPS drug candidate ALG-010133 for chronic hepatitis B.","Phase 1 study showed no meaningful HBsAg reduction at projected efficacious dose of 400 mg.","Higher doses up to 600 mg unlikely to reach 1 log10 IU/mL HBsAg reduction threshold.","No dose-limiting safety findings; decision made jointly with Study Review Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412737,"accession_number":"0001193125-21-333831","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2021-11-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aligos Therapeutics appoints Bridget Martell, M.D. to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Martell appointed as Class III director; term expires at 2023 annual meeting.","She receives $35,000 annual retainer (prorated) and initial option grant of 30,000 shares.","Board size increased from seven to eight directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":412736,"accession_number":"0001171843-21-007561","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q3 net loss $33.1M ($0.78 loss per share); clinical programs advance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $33.1M, EPS $(0.78) vs net loss $33.3M, EPS $(11.00) in Q3 2020.","R&D expenses $28.1M (up from $17.3M) on continued development of three CHB candidates and NASH drug.","Cash, cash equivalents and investments $242.7M as of Sep 30, 2021, down slightly from $243.5M.","Dosing of ASO candidate ALG-020572 in healthy volunteers started; STOPS cohorts (120, 200 mg) fully enrolled.","CTA filed for NASH candidate ALG-055009 (THR-β agonist); dosing in healthy volunteers expected Q4 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":431408,"accession_number":"0001171843-21-005574","cik":1799448,"company_name":"Aligos Therapeutics, Inc.","ticker":"ALGS","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Aligos Q2 2021 net loss $29.8M; $83.6M stock offering; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $29.8M ($0.79 diluted EPS) vs $20.8M ($7.40) year ago; R&D spend $24.6M.","Cash & investments $190.7M at June 30, 2021, down from $243.5M at Dec 2020.","Gross proceeds of $83.6M from July 2021 follow-on stock offering (4.4M shares at $19.00).","STOPS and CAM programs dosing in CHB cohorts; data expected H1 2022.","CTA filed for ASO ALG-020572; NASH drug ALG-055009 CTA on track for Q3 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":35149106.842857145,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}